≡

Multiplex Assay Kit for Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay)

CMD1S; CMH1; MPD1; MYHCB; Myopathy,Distal 1; Myosin heavy chain slow isoform; Myosin heavy chain, cardiac muscle beta isoform

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-101 90
EDTA plasma(n=5) 84-94 90
heparin plasma(n=5) 80-91 85
sodium citrate plasma(n=5) 79-101 84

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 78-103% 79-91% 80-103% 86-93%
EDTA plasma(n=5) 86-94% 92-99% 89-104% 84-101%
heparin plasma(n=5) 99-105% 87-94% 86-101% 80-102%
sodium citrate plasma(n=5) 89-97% 91-101% 78-92% 78-92%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:MYH7) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Life Sciences Cardioprotective effect of cerium oxide nanoparticles in monocrotaline rat model of pulmonary hypertension: A possible implication of endothelin-1 Pubmed:29588134
Archives of Medical Research Irisin vs. Treadmill Exercise in Post Myocardial Infarction Cardiac Rehabilitation in Rats
Passive repetitive stretching increases skeletal muscle mass and myo 17143883
Sci Rep Passive repetitive stretching is associated with greater muscle mass and cross-sectional area in the sarcopenic muscle 34315961
Catalog No. Related products for research use of Rattus norvegicus (Rat) Organism species Applications (RESEARCH USE ONLY!)
RPD418Ra01 Recombinant Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) Positive Control; Immunogen; SDS-PAGE; WB.
PAD418Ra01 Polyclonal Antibody to Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) WB; IHC; ICC; IP.
MAD418Ra21 Monoclonal Antibody to Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) WB; IHC; ICC; IP.
SED418Ra ELISA Kit for Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) Enzyme-linked immunosorbent assay for Antigen Detection.
LMD418Ra Multiplex Assay Kit for Myosin Heavy Chain 7, Cardiac Muscle, Beta (MYH7) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.